Brenton Saunders, David Pyott

Brenton Saunders, David Pyott

In this Nov. 17, 2014 file photo, Allergan CEO David Pyott, left, and Actavis CEO Brenton Saunders, are interviewed on the floor of the New York Stock Exchange. Pyott is set to rake in an estimated $100 million in “golden parachute” payments, according to a study done by pay-tracking firm Equilar at the request of The Associated Press. (AP Photo/Richard Drew)

FILE – In this Nov. 17, 2014 file photo, Allergan CEO David Pyott, left, and Actavis CEO Brenton Saunders, are interviewed on the floor of the New York Stock Exchange. Pyott is set to rake in an estimated $100 million in “golden parachute” payments, according to a study done by pay-tracking firm Equilar at the request of The Associated Press. (AP Photo/Richard Drew)

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.